Evaluation of the Incidence of Rotavirus Infection and the Effectiveness of Vaccination in the Khanty-Mansi Autonomous Ugra District in 2014–2018

Relevance. Rotavirus infection (RVI) is recognized as the main cause of severe gastroenteritis in children worldwide and leads to 527 000 deaths annually.

Aim. Present study was intended to evaluate the effectiveness of anti-epidemic measures and vaccination against RVI in children in Pyt-Yakh, Khanty-Mansiysk Autonomous Okrug-Ugra in 2016–2017.

Materials and methods. An analysis of the incidence of intestinal infection and RVI was carried out within 2 years prior (2014–2015) to and 2 years after (2016–2017) the implementation of anti-epidemic measures.A separate study was conducted to evaluate the safety and efficacy of a live oral pentavalent vaccine in 593 children including 433 who received three doses of the vaccine in 2016–2017.

Results. It was shown that anti-epidemic measures including vaccination decreased the chances of RVI in children aged 0–17 years 1.68 fold in 2017–2018 compared to 2015–2016 (odds ratio (OR) 0.59, 95% confidence interval (CI) 0.49–0.71, p < 0.001). The same data were obtained for children 12 months and younger (OR 0.57, 95% CI 0.35–0.95, р = 0.037) and children aged 1–2 years old (OR 0.62, 95% CI 0.45–0.84, р = 0.002). There were no cases of moderate or severe intestinal infections or hospitalizations in vaccinated population as well as postvaccinal complications.

Conclusion. The incidence of intestinal and rotavirus infections in all population in 2018 compared to 2016decreased by 53% and 72% respectively.

1. The order of the Ministry of Health of the Russian Federation dated March 21, 2014 No. 125-n «On the approval of the national schedule of preventive vaccinations and the schedule of preventive vaccinations according to epidemic indications» (as amended by the order of the Ministry of Healthcare of the Russian Federation of 16.06.2016 No. 370n, No. 175n of 04/13/2017 No. 243n dated April 24, 2019) (In Russ.).

2. The immunological basis for immunization series: module 21: rotavirus. (Immunological basis for immunization series; module 21). World Health Organization. II. Series. ISBN 978 92 4 150264 1 (NLM classification: WC 501) World Health Organization 2011.

3. Prevention of infectious diseases. Intestinal infections. Epidemiological surveillance, laboratory diagnostics and prevention of RVI. Guidelines 3.1.1.2957-11. 3.1.1 (In Russ.).

4. On the state of the sanitary-epidemiological well-being of the population of the Russian Federation in 2018. State report. Moscow, 2019: 254 (In Russ.).

5. Baranov A. A., Namazova-Baranova L. S., Tatochenko V. K. et al. Rotavirus infection of children − an unresolved problem. Overview of vaccine prevention guidelines. Pediatric pharmacology. 2017; 14 (4): 248–257. doi: 10.15690/pf.v14i4.1756 (In Russ.).

6. Grigorovich M. S. Outcomes of acute intestinal infections in children, their determining factors, and optimization of rehabilitation paths. Abstract of dissertation for the degree of Doctor of Medical Sciences. Moscow, 2011 (In Russ.).

7. Zarubinsky V. Ya., Gapon M. N., Akelina O. V. Asymptomatic rotavirus infection: spread and epidemiological significance. Epidemiology and infectious diseases. 2017; 22 (2): 101–105. DOI: http://dx.doi.org/10.18821/1560-9529-2017-22-2-101-105 (In Russ.).

8. Namazova-Baranova L. S., Fedoseenko M. V., Vishneva E. A. et al. Vaccination against rotavirus infection: 10 years of world experience in successful use. Current Pediatrics. 2017; 16 (4): 273–285. doi: 10.15690/vsp.v16i4.1773 (In Russ.).

9. Burnett E, Parashar U, Tate J. Rotavirus Vaccines: effectiveness, safety, and future directions. Pediatr Drugs (2018) 20: 223–233. https://doi.org/10.1007/s40272-018-0283-3.

10. Burnett E, Jonesteller CL, Tate JE, et al. Global impact of rotavirus vaccination on childhood hospitalizations and mortality from diarrhea. J Infect Dis. 2017;215(11):1666– 1672. doi: 10.1093/infdis/jix186.

11. Jonesteller CL, Burnett E, Yen C, et al. Effectiveness of Rotavirus Vaccination: а systematic review of the first decade of global postlicensure data, 2006–2016. Clin Infect Dis. 2017;65(5):840–850. doi: 10.1093/cid/cix369.

12. Pindyck T, Tate JE, Parashar UD (2018). A decade of experience with rotavirus vaccination in the United States – vaccine uptake, effectiveness, and impact, Expert Review of Vaccines, 17; 7: 593–606, DOI: 10.1080/14760584.2018.1489724.

13. Rota Council. Global Introduction Status. Available at: http://rotacouncil.org/vaccine-introduction/global-introduction-status/.

14. Tatochenko V.K., Ozeretskovsky N.A. Immunoprophylaxis-2018: reference book, 13th,. Moscow: Borges, 2018: 272 (In Russ.).

15. Rudakova AV, Harit SM, Podkolzin AT et al. Evaluation of the cost-effectiveness of vaccinating children with a 5-valent rotavirus vaccine in the Russian Federation. Pediatric pharmacology. 2017; 14 (6): 501–507. doi: 10.15690/pf.v14i6.1833 (In Russ.).

16. Rogers MAM, Basu T, Kim C. Lower Incidence Rate of type 1 Diabetes after Receipt of the Rotavirus Vaccine in the United States, 2001–2017. Scientific reports, 2019. Available at: www.nature.com/scientificreports.

17. On the state of sanitary and epidemiological welfare of the population in Khanty-Mansiysk Autonomous Okrug-Ugra in 2018: State report. 2019 (In Russ.).